Center-Authored Papers

Filters: Author is Altman, Jessica K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
P
Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom TR, Hobbs G et al..  2016.  NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(12):1505-1512. Abstract
O
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE et al..  2017.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(7):926-957. Abstract
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE et al..  2013.  Acute myeloid leukemia, version 2.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(9):1047-55. Abstract
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT et al..  2013.  Chronic Myelogenous Leukemia, Version 1.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(11):1327-40. Abstract
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S et al..  2014.  Chronic myelogenous leukemia, version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(11):1590-610. Abstract
C
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK et al..  2014.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology. Abstract